Drugs / EGFR(V)-EDV-Dox
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02766699 | Oct 2016 → Aug 2021 | astrocytoma (excluding glioblastoma), glioblastoma | Engeneic Pty Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR(V)-EDV-Dox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02766699 ↗ |
| Modality | Other / unclassified | “a bacterially derived minicell” NCT02766699 ↗ |
| Route | Intravenous | “administered weekly for 7 weeks via IV 20 minute infusion” NCT02766699 ↗ |
| Target | EGFR | “EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors” NCT02766699 ↗ |